Composition :
Each ml contains : Clindamycin phosphate equivalent to
Clindamycin ....................................................10 mg
Pharmacology:
Rapid in vivo hydrolysis converts Clindamycin phosphate to the antibacterially active clindamycin. Clindamycin in vitro inhibits all Propionibacterium acnes cultures tested. Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.
Indications:
CLINIKA Lotion is indicated in the treatment of acne vulgaris.
Dosage and Administration:
Apply a thin film of CLINIKA Lotion twice daily to affected area.
Warnings and Precautions:
- Use of the topical formulation of clindamycin results in absorption
of the antibiotic from the skin surface. As with orally administered clindamycin when diarrhea occurs, the drug should be discontinued.
- CLINIKA should be prescribed with caution in atopic individuals.
- This drug should be used for pregnant women or nursing mothers
only if clearly needed.
- Safety and effectiveness is pediatric patients under the age of 12
have not been established.
Contraindications:
- Individuals hypersensitive to the drug
- Individuals with a history of regional enteritis or ulcerative colitis
- Individuals with a history of antibiotic-associated colitis.
Drug Interactions:
- Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.
- Antagonism has been demonstrated between clindamycin and erythromycin in vitro . Because of possible clinical significance, these two drugs should not be administered concurrently.
Overdosage:
No specific treatment exists. If an allergic reaction occurs, emergency therapy should be administered including use of corticosteroids, adrenalin and antihistamines.
Presentation:
Bottles of 30 ml in boxes
Reg. No. :DKL9509311241A1 |
